Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program.

Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, Ross A, Schaeffer EM, Gibb EA, Takhar M, Den RB, Lehrer J, Karnes RJ, Freedland SJ, Davicioni E, Spratt DE, Ellis L, Jaffe JD, DʼAmico AV, Kantoff PW, Bradner JE, Mucci LA, Chavarro JE, Loda M, Brown M.

Nat Commun. 2019 Sep 25;10(1):4358. doi: 10.1038/s41467-019-12298-z.

2.

Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'.

Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, Karan C, Realubit RB, Mundi PS, Grunn A, Jäger D, Chabot JA, Fojo AT, Oberstein PE, Hibshoosh H, Milsom JW, Kulke MH, Loda M, Chiosis G, Reidy-Lagunes DL, Califano A.

Nat Genet. 2019 Oct;51(10):1427-1428. doi: 10.1038/s41588-019-0509-5. No abstract available.

PMID:
31548719
3.

A prospective study of intraprostatic inflammation, focal atrophy, and progression to lethal prostate cancer.

Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, Giunchi F, Platz EA, De Marzo AM, Mucci LA, Fiorentino M, Ebot EM.

Cancer Epidemiol Biomarkers Prev. 2019 Sep 18. pii: cebp.0713.2019. doi: 10.1158/1055-9965.EPI-19-0713. [Epub ahead of print]

PMID:
31533941
4.

Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.

Hamid AA, Gray KP, Huang Y, Bowden M, Pomerantz M, Loda M, Sweeney CJ.

Eur Urol Oncol. 2019 Sep;2(5):475-482. doi: 10.1016/j.euo.2018.09.003. Epub 2018 Oct 4.

PMID:
31411988
5.

The role of lineage plasticity in prostate cancer therapy resistance.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.

Clin Cancer Res. 2019 Jul 30. pii: clincanres.1423.2019. doi: 10.1158/1078-0432.CCR-19-1423. [Epub ahead of print]

PMID:
31363002
6.

Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer.

Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, Ebot EM, Isikbay M, Finn SP, Giovannucci EL, Lis RT, Loda M, Parmigiani G, Lotan T, Kantoff PW, Mucci LA, Graff RE.

Int J Cancer. 2019 Jul 18. doi: 10.1002/ijc.32577. [Epub ahead of print]

PMID:
31318977
7.

When fat goes down, prostate cancer is on the ropes.

Zadra G, Loda M.

Mol Cell Oncol. 2019 Apr 16;6(3):1595308. doi: 10.1080/23723556.2019.1595308. eCollection 2019.

PMID:
31131311
8.

Aneuploidy drives lethal progression in prostate cancer.

Stopsack KH, Whittaker CA, Gerke TA, Loda M, Kantoff PW, Mucci LA, Amon A.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11390-11395. doi: 10.1073/pnas.1902645116. Epub 2019 May 13.

PMID:
31085648
9.

Genomic correlates of clinical outcome in advanced prostate cancer.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL.

Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436. doi: 10.1073/pnas.1902651116. Epub 2019 May 6.

10.

The Metabolic Landscape of Prostate Cancer.

Giunchi F, Fiorentino M, Loda M.

Eur Urol Oncol. 2019 Feb;2(1):28-36. doi: 10.1016/j.euo.2018.06.010. Epub 2018 Jul 19. Review.

PMID:
30929843
11.

AKT1low quiescent cancer cells in ductal carcinoma in situ of the breast.

Kabraji S, Sole X, Huang Y, Bango C, Sgroi D, Loda M, Ramaswamy S.

NPJ Breast Cancer. 2019 Mar 21;5:10. doi: 10.1038/s41523-019-0105-y. eCollection 2019.

12.

Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.

Randall EC, Zadra G, Chetta P, Lopez BGC, Syamala S, Basu SS, Agar JN, Loda M, Tempany CM, Fennessy FM, Agar NYR.

Mol Cancer Res. 2019 May;17(5):1155-1165. doi: 10.1158/1541-7786.MCR-18-1057. Epub 2019 Feb 11.

PMID:
30745465
13.

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D'Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640. doi: 10.1073/pnas.1808834116. Epub 2018 Dec 21.

14.

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.

Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ.

Eur Urol. 2019 Jul;76(1):89-97. doi: 10.1016/j.eururo.2018.11.045. Epub 2018 Dec 12.

PMID:
30553611
15.

Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune Infiltration.

Wang Z, Cao S, Morris JS, Ahn J, Liu R, Tyekucheva S, Gao F, Li B, Lu W, Tang X, Wistuba II, Bowden M, Mucci L, Loda M, Parmigiani G, Holmes CC, Wang W.

iScience. 2018 Nov 30;9:451-460. doi: 10.1016/j.isci.2018.10.028. Epub 2018 Nov 2.

16.

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M.

Mol Cancer Res. 2019 Feb;17(2):446-456. doi: 10.1158/1541-7786.MCR-18-0440. Epub 2018 Oct 17.

PMID:
30333152
18.

Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease.

Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Carcinogenesis. 2018 Dec 31;39(12):1431-1437. doi: 10.1093/carcin/bgy112.

PMID:
30165429
19.

A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status.

Stopsack KH, Gonzalez-Feliciano AG, Peisch SF, Downer MK, Gage RA, Finn S, Lis RT, Graff RE, Pettersson A, Pernar CH, Loda M, Kantoff PW, Ahearn TU, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP).

Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1231-1233. doi: 10.1158/1055-9965.EPI-18-0510. Epub 2018 Aug 14.

20.

Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.

Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, Mostaghel EA, Nelson PS, Taplin ME, Balk SP.

Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19.

21.

Specific 18F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin.

Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, Hooker JM, Loda M, Mahmood U.

J Nucl Med. 2018 Oct;59(10):1538-1543. doi: 10.2967/jnumed.118.208785. Epub 2018 May 31.

22.

LSD1: A single target to combat lineage plasticity in lethal prostate cancer.

Ellis L, Loda M.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4530-4531. doi: 10.1073/pnas.1804205115. Epub 2018 Apr 16. No abstract available.

23.

Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer.

Nowinski S, Santaolalla A, O'Leary B, Loda M, Mirchandani A, Emberton M, Van Hemelrijck M, Grigoriadis A.

Oncotarget. 2018 Feb 5;9(16):12812-12824. doi: 10.18632/oncotarget.24400. eCollection 2018 Feb 27.

24.

Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

Zadra G, Loda M.

Cold Spring Harb Perspect Med. 2018 Oct 1;8(10). pii: a030569. doi: 10.1101/cshperspect.a030569. Review.

PMID:
29229664
25.

Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer.

Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):193-200. doi: 10.1158/1055-9965.EPI-17-0547. Epub 2017 Nov 22.

26.

MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.

Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):201-207. doi: 10.1158/1055-9965.EPI-17-0637. Epub 2017 Nov 15.

27.

AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth.

Alves CP, Dey-Guha I, Kabraji S, Yeh AC, Talele NP, Solé X, Chowdhury J, Mino-Kenudson M, Loda M, Sgroi D, Borresen-Dale AL, Russnes HG, Ross KN, Ramaswamy S.

Mol Cancer Ther. 2018 Jan;17(1):254-263. doi: 10.1158/1535-7163.MCT-16-0868. Epub 2017 Oct 20.

28.

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.

Calagua C, Russo J, Sun Y, Schaefer R, Lis R, Zhang Z, Mahoney K, Bubley GJ, Loda M, Taplin ME, Balk SP, Ye H.

Clin Cancer Res. 2017 Nov 15;23(22):6812-6822. doi: 10.1158/1078-0432.CCR-17-0807. Epub 2017 Sep 11.

29.

Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer.

Tyekucheva S, Bowden M, Bango C, Giunchi F, Huang Y, Zhou C, Bondi A, Lis R, Van Hemelrijck M, Andrén O, Andersson SO, Watson RW, Pennington S, Finn SP, Martin NE, Stampfer MJ, Parmigiani G, Penney KL, Fiorentino M, Mucci LA, Loda M.

Nat Commun. 2017 Sep 4;8(1):420. doi: 10.1038/s41467-017-00460-4.

30.

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.

Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M, Ramaswamy S.

Breast Cancer Res. 2017 Aug 1;19(1):88. doi: 10.1186/s13058-017-0877-7.

31.

Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.

Crawley D, Chandra A, Loda M, Gillett C, Cathcart P, Challacombe B, Cook G, Cahill D, Santa Olalla A, Cahill F, George G, Rudman S, Van Hemelrijck M.

BMC Cancer. 2017 Jul 21;17(1):494. doi: 10.1186/s12885-017-3458-3.

32.

Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA.

Cancer. 2017 Nov 1;123(21):4130-4138. doi: 10.1002/cncr.30831. Epub 2017 Jul 12.

33.

Fatty Acid Synthase and Acetyl-CoA Carboxylase Are Expressed in Nodal Metastatic Melanoma But Not in Benign Intracapsular Nodal Nevi.

Saab J, Santos-Zabala ML, Loda M, Stack EC, Hollmann TJ.

Am J Dermatopathol. 2018 Apr;40(4):259-264. doi: 10.1097/DAD.0000000000000939.

PMID:
28654463
34.

Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P, Cotter MB, Bowden M, Lis RT, Zhao SG, Wu Q, Feng FY, Loda M, He HH, Liu XS, Brown M.

Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5207-E5215. doi: 10.1073/pnas.1617467114. Epub 2017 Jun 13.

35.

Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer.

Giunchi F, Jordahl K, Bollito E, Colecchia M, Patriarca C, D'Errico A, Vasuri F, Malvi D, Fornari A, Bonetti LR, Corti B, Papotti M, DeGiuli P, Loda M, Montironi R, Fiorentino M, Rider JR.

Virchows Arch. 2017 Jun;470(6):711-715. doi: 10.1007/s00428-017-2123-1. Epub 2017 Apr 12.

PMID:
28405833
36.

Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer.

Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB.

Clin Cancer Res. 2017 Aug 15;23(16):4592-4601. doi: 10.1158/1078-0432.CCR-16-2245. Epub 2017 Apr 7.

37.

Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG.

Graff RE, Judson G, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A.

Prostate. 2017 May;77(6):647-653. doi: 10.1002/pros.23312. Epub 2017 Jan 19.

38.

Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues.

Cacciatore S, Zadra G, Bango C, Penney KL, Tyekucheva S, Yanes O, Loda M.

Mol Cancer Res. 2017 Apr;15(4):439-447. doi: 10.1158/1541-7786.MCR-16-0262. Epub 2017 Jan 10.

39.

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.

Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW, Goodrich MM, Labbé DP, Gomez EC, Wang J, Long HW, Xu B, Brown M, Loda M, Sawyers CL, Ellis L, Goodrich DW.

Science. 2017 Jan 6;355(6320):78-83. doi: 10.1126/science.aah4199.

40.

Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment.

Staunton L, Tonry C, Lis R, Espina V, Liotta L, Inzitari R, Bowden M, Fabre A, O'Leary J, Finn SP, Loda M, Pennington SR.

Mol Cancer Res. 2017 Mar;15(3):281-293. doi: 10.1158/1541-7786.MCR-16-0358. Epub 2017 Jan 5.

41.

ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes.

Caliò A, Bria E, Pilotto S, Gilioli E, Nottegar A, Eccher A, Cima L, Santo A, Pedron S, Turri G, Knuutila S, Chilosi M, Vanzo F, Bogina G, Terzi A, Tortora G, Scarpa A, Loda M, Martignoni G, Brunelli M.

Cancer Biomark. 2017;18(2):215-220. doi: 10.3233/CBM-161680.

PMID:
28009326
42.

The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.

Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA.

Cancer Metab. 2016 Dec 7;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016.

43.

Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.

Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, Cichowski K.

Cancer Discov. 2017 Feb;7(2):202-217. doi: 10.1158/2159-8290.CD-16-0520. Epub 2016 Dec 14.

44.

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.

Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M.

J Clin Invest. 2016 Nov 1;126(11):4387. doi: 10.1172/JCI90690. Epub 2016 Nov 1. No abstract available.

45.

Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Sinnott JA, Peisch SF, Tyekucheva S, Gerke T, Lis R, Rider JR, Fiorentino M, Stampfer MJ, Mucci LA, Loda M, Penney KL.

Clin Cancer Res. 2017 Jan 1;23(1):81-87. doi: 10.1158/1078-0432.CCR-16-1245. Epub 2016 Sep 23.

46.

Challenging Roadblocks to Cancer Cure.

Loda M.

Cancer Res. 2016 Sep 1;76(17):4924-30. doi: 10.1158/0008-5472.CAN-16-1443. Epub 2016 Aug 12.

47.

Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.

Yang M, Zu K, Mucci LA, Rider JR, Fiorentino M, Clinton SK, Loda M, Stampfer MJ, Giovannucci E.

Cancer Causes Control. 2016 Aug;27(8):1043-7. doi: 10.1007/s10552-016-0782-x. Epub 2016 Jul 5.

48.

Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer.

Priolo C, Loda M.

Mol Cell Oncol. 2015 Jan 23;2(4):e1001197. doi: 10.1080/23723556.2014.1001197. eCollection 2015 Oct-Dec.

49.

Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression.

Ahearn TU, Tchrakian N, Wilson KM, Lis R, Nuttall E, Sesso HD, Loda M, Giovannucci E, Mucci LA, Finn S, Shui IM.

J Clin Endocrinol Metab. 2016 Jun;101(6):2520-7. doi: 10.1210/jc.2016-1082. Epub 2016 Apr 26.

50.

Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression.

Graff RE, Meisner A, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA, Pettersson A.

Br J Cancer. 2016 Apr 12;114(8):939-44. doi: 10.1038/bjc.2016.61. Epub 2016 Mar 17.

Supplemental Content

Support Center